6 citations
,
August 2023 in “Fertility and Sterility”
The 2023 guideline for PCOS suggests using updated diagnostic criteria, assessing related health risks, and recommends lifestyle changes and specific treatments for symptoms and fertility issues.
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
The user experienced improved hair growth using Minoxidil twice daily, finasteride 1.25mg once daily, weekly dermarolling, supplements, and occasional ketoconazole shampoo for 5.5 months, but noticed hair shedding again after switching types of Minoxidil. Despite returning to the original Minoxidil, the user's hair condition worsened and shedding continued.
PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.
Dutasteride and finasteride have similar risks of sexual dysfunction for treating androgenetic alopecia. Users experience varying side effects, indicating individual differences in drug reactions.